Bristol-Myers Squibb Co
BMY46.350USD
+0.150+0.32%
Fechamento 09/15, 16:00（ET）Cotações atrasadas em 15 min
94.32BValor de mercado
18.68P/L TTM
Mais detalhes de Bristol-Myers Squibb Co Empresa
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Informações da empresa
Código da empresaBMY
Nome da EmpresaBristol-Myers Squibb Co
Data de listagemMar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Número de funcionários34100
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 17
EndereçoRoute 206 And Province Line Road
CidadePRINCETON
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal08543
Telefone16092524621
Sitehttps://www.bms.com
Código da empresaBMY
Data de listagemMar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.84K
+6.22%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.84K
+6.22%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Eliquis
3.56B
31.83%
Opdivo
2.27B
20.30%
Revlimid
936.00M
8.36%
Orencia
770.00M
6.87%
Pomalyst/Imnovid
659.00M
5.88%
Outro
3.00B
26.76%
Por RegiãoUSD
Nome
Receita
Proporção
United States
7.87B
70.29%
International
3.11B
27.77%
other
218.00M
1.95%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Eliquis
3.56B
31.83%
Opdivo
2.27B
20.30%
Revlimid
936.00M
8.36%
Orencia
770.00M
6.87%
Pomalyst/Imnovid
659.00M
5.88%
Outro
3.00B
26.76%
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
4.88%
State Street Global Advisors (US)
4.65%
Charles Schwab Investment Management, Inc.
3.48%
JP Morgan Asset Management
3.31%
Outro
74.14%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
4.88%
State Street Global Advisors (US)
4.65%
Charles Schwab Investment Management, Inc.
3.48%
JP Morgan Asset Management
3.31%
Outro
74.14%
Tipos de investidores
Investidores
Proporção
Investment Advisor
46.68%
Investment Advisor/Hedge Fund
25.41%
Research Firm
2.90%
Pension Fund
2.54%
Bank and Trust
2.27%
Sovereign Wealth Fund
1.75%
Hedge Fund
1.14%
Insurance Company
0.16%
Family Office
0.06%
Outro
17.09%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
4180
1.70B
83.46%
+31.40M
2025Q1
4287
1.68B
82.63%
+10.66M
2024Q4
4261
1.65B
81.14%
+17.04M
2024Q3
4116
1.60B
78.69%
-22.73M
2024Q2
4105
1.59B
78.35%
-83.12M
2024Q1
4118
1.64B
80.97%
+13.32M
2023Q4
4115
1.60B
78.83%
-46.39M
2023Q3
4042
1.63B
77.83%
-55.50M
2023Q2
4082
1.66B
78.77%
-34.93M
2023Q1
4110
1.66B
78.74%
-34.09M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
190.47M
9.36%
+1.45M
+0.77%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
97.77M
4.8%
+752.85K
+0.78%
Mar 31, 2025
State Street Global Advisors (US)
94.83M
4.66%
-310.27K
-0.33%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
60.61M
2.98%
+306.43K
+0.51%
Mar 31, 2025
JP Morgan Asset Management
69.89M
3.43%
+6.79M
+10.76%
Mar 31, 2025
Capital International Investors
66.47M
3.27%
+20.60M
+44.91%
Mar 31, 2025
Geode Capital Management, L.L.C.
45.45M
2.23%
+1.06M
+2.39%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
35.18M
1.73%
+2.58M
+7.92%
Dec 31, 2024
Columbia Threadneedle Investments (US)
29.03M
1.43%
+534.70K
+1.88%
Mar 31, 2025
Wellington Management Company, LLP
23.73M
1.17%
+17.75M
+296.96%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qua, 6 de ago
Atualizado em: qua, 6 de ago
Nome
Proporção
First Trust NASDAQ Pharmaceuticals ETF
5.91%
LSV Disciplined Value ETF
4.06%
iShares U.S. Pharmaceuticals ETF
3.88%
Coastal Compass 100 ETF
3.81%
Schwab U.S. Dividend Equity ETF
3.57%
Cullen Enhanced Equity Income ETF
3.33%
SPDR S&P Pharmaceuticals ETF
3.26%
Tema Oncology ETF
3.16%
VanEck Pharmaceutical ETF
3.1%
Brookstone Value Stock ETF
3%
Ver Mais
First Trust NASDAQ Pharmaceuticals ETF
Proporção5.91%
LSV Disciplined Value ETF
Proporção4.06%
iShares U.S. Pharmaceuticals ETF
Proporção3.88%
Coastal Compass 100 ETF
Proporção3.81%
Schwab U.S. Dividend Equity ETF
Proporção3.57%
Cullen Enhanced Equity Income ETF
Proporção3.33%
SPDR S&P Pharmaceuticals ETF
Proporção3.26%
Tema Oncology ETF
Proporção3.16%
VanEck Pharmaceutical ETF
Proporção3.1%
Brookstone Value Stock ETF
Proporção3%
Dividendo
Um total de
22.71B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Jun 14, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option
Jul 07, 2023
Aug 01, 2023
Jul 06, 2023
Mar 03, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023
Apr 10, 2023
May 01, 2023
Apr 06, 2023
Dec 08, 2022
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023
Jan 06, 2023
Feb 01, 2023
Jan 05, 2023
Sep 14, 2022
BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022
Oct 07, 2022
Nov 01, 2022
Oct 06, 2022
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
